首页> JAMA> Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.

导出 OA

翻译打印收藏纠错

第一作者： Kausik K,Ray

第一单位： Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, United Kingdom.

作者： Kausik K,Ray ^[1] ; Stephen J,Nicholls ^[2] ; Kevin A,Buhr ^[3] ; Henry N,Ginsberg ^[4] ; Jan O,Johansson ^[5] ; Kamyar,Kalantar-Zadeh ^[6] ; Ewelina,Kulikowski ^[5] ; Peter P,Toth ^[7] ; Norman,Wong ^[5] ; Michael,Sweeney ^[5] ; Gregory G,Schwartz ^[8] ; BETonMACE Investigators and Committees

作者单位： Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, United Kingdom. ^[1] Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. ^[2] Statistical Data Analysis Center, University of Wisconsin-Madison. ^[3] Irving Institute for Clinical and Translational Research, Columbia University, New York, New York. ^[4] Resverlogix Corporation, Calgary, Alberta, Canada. ^[5] Division of Nephrology and Hypertension, University of California-Irvine. ^[6] CGH Medical Center, Sterling, Illinois, and Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland. ^[7] Division of Cardiology, University of Colorado School of Medicine, Aurora. ^[8]